Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 As a Prognostic Biomarker in Gastric Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2020 Oct 2

PMID 33005257

Citations 7

Authors

Yangyu Zhang

Lili Qin

Xiaobo Ma

Yueqi Wang

Yanhua Wu

Jing Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Degradation of the extracellular matrix (ECM), an essential step in tumour invasion and metastasis, is mainly dependent on the activities of both matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). This study aimed to explore whether expression of MMP-7 and TIMP-1 alone and in combination can be used as a prognostic marker for gastric cancer (GC).

Method: A total of 285 patients who had undergone tumourectomy for GC were included. Gastric tumour tissues were stained immunohistochemically to evaluate expression of MMP-7 and TIMP-1.

Results: Expression of MMP-7 was associated with tumour N stage and neural invasion. Multivariate Cox regression analysis suggested that expression of MMP-7 or TIMP-1 alone cannot serve as an indicator of patient prognosis; however, coexpression of MMP-7 and TIMP-1 was found to be an independent predictive factor of overall survival in patients with GC (HR = 1.74, 95% CI: 1.08-2.80). The results of stratified analysis also showed that the predictive value of MMP-7 and TIMP-1 coexpression was stronger in patients with N3 stage disease and not receiving chemotherapy.

Conclusions: In conclusion, coexpression of MMP-7 and its inhibitor TIMP-1 in gastric tumour tissues is a potential prognostic marker for GC. Greater knowledge of protein expression will lead to new paradigms and possible improvements in therapeutics.

Citing Articles

Identification of Hub Genes and Potential Pathogenesis in Gastric Cancer Based on Integrated Gene Expression Profile Analysis.

Luu Truong Thanh H, Hoang T, Hoang Van H Asian Pac J Cancer Prev. 2024; 25(3):885-892.

PMID: 38546071 PMC: 11152393. DOI: 10.31557/APJCP.2024.25.3.885.

The role of senescence genes in the treatment, prognosis, and tumor microenvironment of gastric cancer.

Xuan J, Li F, Li J, Gong C, Li J, Mo Z Am J Transl Res. 2024; 15(12):6926-6938.

PMID: 38187003 PMC: 10767519.

Common Core Genes Play Vital Roles in Gastric Cancer With Different Stages.

Yu Z, Liang C, Tu H, Qiu S, Dong X, Zhang Y Front Genet. 2022; 13:881948.

PMID: 35938042 PMC: 9352954. DOI: 10.3389/fgene.2022.881948.

Could inhibition of metalloproteinases be used to block the process of metastasis?.

Alba J, Barcia R, Gutierrez-Berzal J, Ramos-Martinez J Cell Biochem Funct. 2022; 40(6):600-607.

PMID: 35789101 PMC: 9544369. DOI: 10.1002/cbf.3730.

Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer.

Kang D, Kim I Biomedicines. 2022; 10(6).

PMID: 35740397 PMC: 9220323. DOI: 10.3390/biomedicines10061376.

References

Bigelow R, Williams B, Carroll J, Daves L, Cardelli J . TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2008; 117(1):31-44. DOI: 10.1007/s10549-008-0170-7. View

Jackson H, Defamie V, Waterhouse P, Khokha R . TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2016; 17(1):38-53. DOI: 10.1038/nrc.2016.115. View

Naruo S, Kanayama H, Takigawa H, Kagawa S, Yamashita K, Hayakawa T . Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol. 1994; 1(3):228-31. DOI: 10.1111/j.1442-2042.1994.tb00040.x. View

Grunnet M, Mau-Sorensen M, Brunner N . Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013; 48(8):899-905. DOI: 10.3109/00365521.2013.812235. View

Wroblewski L, Noble P, Pagliocca A, Pritchard D, Hart C, Campbell F . Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci. 2003; 116(Pt 14):3017-26. DOI: 10.1242/jcs.00518. View

Holten-Andersen M, Murphy G, Nielsen H, Pedersen A, Christensen I, Hoyer-Hansen G . Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer. 1999; 80(3-4):495-503. PMC: 2362309. DOI: 10.1038/sj.bjc.6690384. View

Fanelli M, Domingos Chinen L, Dirlei Begnami M, Costa Jr W, Fregnami J, Soares F . The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012; 61(2):153-61. DOI: 10.1111/j.1365-2559.2011.04139.x. View

Koskensalo S, Mrena J, Wiksten J, Nordling S, Kokkola A, Hagstrom J . MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010; 31(3):149-55. DOI: 10.1007/s13277-010-0020-1. View

Sorsa T, Tjaderhane L, Salo T . Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004; 10(6):311-8. DOI: 10.1111/j.1601-0825.2004.01038.x. View

10.

Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T . Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003; 253(1-2):269-85. DOI: 10.1023/a:1026028303196. View

11.

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T . Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993; 53(22):5365-9. View

12.

Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y . Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2005; 231(1):20-7. DOI: 10.1177/153537020623100103. View

13.

Liu X, Kawauchi S, Oga A, Tsushimi K, Tsushimi M, Furuya T . Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn J Cancer Res. 2002; 93(3):291-5. PMC: 5926963. DOI: 10.1111/j.1349-7006.2002.tb02171.x. View

14.

Holten-Andersen M, Stephens R, Nielsen H, Murphy G, Christensen I, Brunner N . High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000; 6(11):4292-9. View

15.

Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S . Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomartker for invasion and its impact on survival. Cancer. 2001; 91(9):1739-44. DOI: 10.1002/1097-0142(20010501)91:9<1739::aid-cncr1192>3.0.co;2-9. View

16.

Joo Y, Seo K, Kim H, Rew J, Park C, Kim S . Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci. 2000; 45(1):114-21. DOI: 10.1023/a:1005421713137. View

17.

Mroczko B, Lukaszewicz-Zajac M, Groblewska M, Czyzewska J, Gryko M, Guzinska-Ustymowicz K . Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue. Folia Histochem Cytobiol. 2010; 47(3):511-6. DOI: 10.2478/v10042-009-0071-6. View

18.

Kapoor C, Vaidya S, Wadhwan V, Kaur G, Pathak A . Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther. 2016; 12(1):28-35. DOI: 10.4103/0973-1482.157337. View

19.

Bufu T, Di X, Yilin Z, Gege L, Xi C, Ling W . Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. Anticancer Drugs. 2018; 29(6):530-538. DOI: 10.1097/CAD.0000000000000621. View

20.

Wang W, Chen P, Wang H, Liang W, Su Y . Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 2006; 27(5):1113-20. DOI: 10.1093/carcin/bgi351. View